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Abstract
Purpose The proper validation of prognostic biomarkers is
an important clinical issue in breast cancer research.
MicroRNAs (miRNAs) have emerged as a new class of
promising breast cancer biomarkers. In the present work, we
developed an integrated online bioinformatic tool to validate
the prognostic relevance of miRNAs in breast cancer.
Methods A database was set up by searching the GEO, EGA,
TCGA, and PubMed repositories to identify datasets with
published miRNA expression and clinical data. Kaplan–
Meier survival analysis was performed to validate the
prognostic value of a set of 41 previously published survival-
associated miRNAs.
Results All together 2178 samples from four independent
datasets were integrated into the system including the
expression of 1052 distinct human miRNAs. In addition, the
web-tool allows for the selection of patients, which can be
filtered by receptors status, lymph node involvement, histo-
logical grade, and treatments. The complete analysis tool can
be accessed online at: www.kmplot.com/mirpower. We used
this tool to analyze a large number of deregulated miRNAs
associated with breast cancer features and outcome, and
confirmed the prognostic value of 26 miRNAs. A significant
correlation in three out of four datasets was validated only for
miR-29c and miR-101.
Conclusions In summary, we established an integrated
platform capable to mine all available miRNA data to
perform a survival analysis for the identification and vali-
dation of prognostic miRNA markers in breast cancer.
Keywords Breast cancer  Biomarkers  MicroRNAs 
Gene expression  Prognosis  Survival
Introduction
Breast cancer represents the most frequent malignancy, and is
still a leading cause of cancer-related death in women world-
wide [1]. Distinct histopathological features are routinely used
as prognostic and predictive markers, ultimately driving clini-
cal treatment decisions [2]. However, these characteristics are
not able to capture the heterogeneity of breast cancer and to
accurately predict patient outcome [3]. Data derived from
genome-wide studies provided novel insights into breast cancer
complexity, leading to the refinement of the breast cancer
molecular classification, and enabling a deeper understanding
of the clinical course of the disease.
MicroRNAs (miRNAs) are small non-coding RNA
molecules regulating gene expression and widely influenc-
ing pathways associated with tumor development, progres-
sion, and response to therapy [4]. Several studies have
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demonstrated that miRNAs expression profiles could accu-
rately classify molecular breast cancer subtypes and identify
patients with different clinical outcome [5–8]. A large
number of prognostic miRNAs for breast cancer have been
described so far [9, 10]. However, there is an evident
imbalance between the large amount of published candidate
biomarkers and the reduced number of marker that have
actually impacted clinical practice. The clinical and molec-
ular heterogeneity of the breast cancer cohorts used in dif-
ferent studies, as well as methodological biases regarding
reproducibility and standardization, have limited the iden-
tification of specific miRNAs as robust predictors of breast
cancer patient outcome. Thus, to improve risk stratification
and clinical decision making, the validation of the prognostic
value of miRNAs in breast cancer is imperative.
In the present work, we aimed to structure a novel
analytical web-tool based on the integration of miRNA
expression and clinical data from different breast cancer
datasets, and directed to validate the prognostic clinical
relevance of miRNAs. In summary, this bioinformatic tool
is able to perform a real-time analysis of published miRNA
datasets in order to measure the power of miRNAs as
predictor of survival in breast cancer patients.
Methods
MiRNA gene expression database
A database was established using miRNA expression data
downloaded from gene expression omnibus (GEO) (http://
www.ncbi.nlm.nih.gov/geo/), the cancer genome Atlas
(TCGA) (http://cancergenome.nih.gov/), European gen-
ome-phenome archive (EGA) (https://ega.crg.eu/), and
PubMed (http://www.pubmed.com). For the database, the
keywords ‘‘breast cancer,’’ and ‘‘miRNA’’ or ‘‘microRNA’’
were used as the search terms. Only publications with
available expression data, clinical survival information, and
at least 50 breast cancer patients were included. All samples
were checked using the ranked expression of all genes to
identify repeatedly published microarrays. Four studies were
identified that met our criteria [11–14]. Replicates were
removed, and the published normalized expression data
without a renormalization were used in the statistical com-
putations. Detailed characteristics for each dataset are given
in Online Resource 1. Only overall survival (OS) data were
published for each of these datasets. Each dataset was pro-
cessed separately.
Statistical analysis
For each analysis, the data were loaded into the R statistical
environment, where calculations were performed. In case
of missing data, the samples are excluded from the analysis
(this is also the reason for the reduction in the sample
number in case a filter is employed). The package ‘‘sur-
vival’’ is used to calculate and plot Kaplan–Meier survival
curves, and the number-at-risk is indicated below the main
plot. Hazard ratio (HR), 95 % confidence intervals (CI),
and log-rank p values were calculated and displayed.
Proportional hazard was computed by the ‘‘coxph’’ pack-
age. Statistical significance was set at p B 0.05. Bonferroni
correction was executed for studies simultaneously pub-
lishing multiple miRNA biomarker candidates.
Online analysis interface
A web interface was set up to enable reproduction of
computations in a platform-independent user interface. The
entire dataset with clinical data is loaded into a PostgreSQL
database which then enables immediate filtering of the
data. The interactivity of the service is increased by the
usage of JavaScript and Ajax technologies. The server is
running on Debian Linux (www.debian.org) and is pow-
ered by Apache (www.apache.org). The server scripts were
made in hypertext preprocessor (PHP), which controls both
the analysis requests and delivers the results.
Identification of miRNAs associated with prognosis
in breast cancer
A PubMed search was performed using the keywords ‘‘breast
cancer’’, ‘‘miRNA’’, ‘‘microRNA’’, ‘‘overall survival’’, and
‘‘biomarker’’ to identify miRNAs described in the literature
as potential prognostic biomarkers for breast cancer. Only
studies published in English were considered. We uncovered
41 miRNAs associated with OS in breast cancer tissues
(Online Resource 2). Then, using the original publications
and PubMed gene, we added a unique gene symbol for each
of the miRNAs and linked these to the corresponding probe
IDs in each dataset. The capability of these genes to predict
survival was measured by running the analysis in the online
tool. The validation analysis was performed in each of the
four cohorts separately. The median expression was used for
splitting the patients into cohorts during the analysis.
Results
Database setup
We identified four studies meeting our criteria in the GEO,
TCGA, EGA, and PubMed. These included 634 patients in
the TCGA, 1262 patients in the Metabric, 181 patients in the
GSE40267, and 101 patients in the GSE19783 [11–14].
Estrogen receptor (ER)-positive patients represent 72.1 % of
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all samples. GSE40267 has predominantly ER-negative
samples (81.8 %; Online Resource 1). The TCGA dataset has
a high proportion of progesterone receptor (PGR)-positive
samples (64.0 %), while GSE40267 has only 16.0 % PGR-
positive patients. HER2-positive patients account for 16.7 %
of the entire database (5.5–16.8 % in the individual datasets;
Online Resource 1). Only OS data were published for each of
these datasets, and the mean follow-up is 71.6 months.
However, individual datasets have a high difference in the
length of follow-up: only 25.0 months for TCGA,
62.4 months for GSE40267, 86.8 months for GSE19783, and
94.2 months for the Metabric samples. An overview of the
available clinical data is presented in Fig. 1. The Metabric
dataset also had published detailed treatment information.
Here, a set of patients were systemically untreated—these
patients have neither received hormonal therapy nor
chemotherapy nor radiotherapy (n = 199). When comparing
clinical characteristics between the systemically untreated
and treated patients, almost all the untreated patients were
node negative (91.8 vs. 46.5 %, p\ 1E-16).
The entire database contains 1052 distinct human
miRNAs, of which 555 miRNAs are measured on one
platform only, 141 miRNAs are measured on two, 148
miRNAs are measured on three, and 207 miRNAs are
measured on each platform. Proportion of overlapping
miRNAs among the four different platforms used ranged
between 23.1 % (TCGA v GSE1973) and 75.7 %
(GSE19673 v GSE40267) (Fig. 2; Online Resource 3).
Online analysis interface
The entire computational pipeline with the associated data-
bases is made accessible for reanalysis in an online acces-
sible registration-free system. To measure the association
between a queried miRNA and survival, the samples are
grouped according to the median (or upper or lower quartile)
expression of the selected miRNA, and then the two groups
are compared by Cox proportional hazards regression, and a
Fig. 1 Clinical characteristics of the samples included in the cohorts
used in this study. a Availability of clinical data for each of the datasets.
b Proportions of receptor status for ER, PGR, and HER2 in each dataset.
Receptor status is based on immunohistochemistry, with the exception
of the gene array-based Metabric (*). c Length of follow-up in each
dataset. d Survival differences according to molecular subtype
Fig. 2 Characteristics of overlapping miRNAs among different
datasets. a The overlap of miRNAs measured in the four different
studies. b Proportion of miRNAs measured by one, two, three, or all
four studies
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Table 1 MiRNAs with validated prognostic values in breast cancer
MiRNA Patients Metabric TCGA
n HR 95 % CI p value q value n HR 95 % CI p value q value
let-7b Het 1262 0.78 0.64–0.95 1.3E202 7.5E-03 579 0.68 0.41–1.13 1.3E-01 0.10
let-7 g Het 1262 0.79 0.65–0.96 2.0E202 9.5E-03 579 0.92 0.56–1.53 7.6E-01 0.33
miR-10b Het 1262 0.74 0.61–0.90 3.0E203 3.2E-03 579 0.81 0.49–1.34 4.0E-01 0.22
miR-15a TNBC 203 0.62 0.39–0.98 3.9E202 1.6E-02 95 0.57 0.17–1.93 3.6E-01 0.22
miR-21 TNBC 203 1.03 0.66–1.61 8.9E-01 2.6E-01 95 0.73 0.22–2.42 6.0E-01 0.28
miR-22 Het 1262 1.3 1.0–1.5 1.8E202 9.1E-03 579 2.05 1.22–3.45 5.6E203 0.02
miR-27b TNBC 203 0.95 0.61–1.48 8.2E-01 2.5E-01 95 1.64 0.48–5.65 4.2E-01 0.22
miR-29c Het 1262 0.72 0.59–0.88 1.2E203 1.5E-03 579 0.46 0.27–0.77 2.5E203 0.01
miR-99a LumA;ER?/HER2- 546 0.77 0.54–1.11 1.6E-01 5.7E-02 327 0.4 0.15–1.08 6.0E-02 0.05
Het 1262 0.71 0.58–0.87 8.0E204 1.2E-03 579 0.74 0.45–1.22 2.3E-01 0.16
miR-100 Het 1262 0.75 0.62–0.92 5.2E203 4.3E-03 579 0.71 0.43–1.18 1.8E-01 0.13
miR-101 Het 1262 0.64 0.52–0.78 1.0E205 4.1E-05 579 0.46 0.28–0.77 2.4E203 0.01
miR-125b LumA; ER?/HER2- 546 0.65 0.45-0.95 2.4E202 1.1E-02 327 0.76 0.29–1.99 5.7E-01 0.28
miR-146a TNBC 203 0.64 0.41–1.01 5.1E202 1.9E-02 95 0.96 0.28–3.3 9.5E-01 0.37
miR-146 TNBC 203 0.61 0.39–0.96 3.1E202 1.3E-02 95 0.88 0.27–2.93 8.4E-01 0.34
miR-155 TNBC 203 0.52 0.33–0.82 4.7E203 4.3E-03 95 0.58 0.17–1.95 3.7E-01 0.22
miR-181a TNBC 203 1.36 0.87-2.13 1.7E-01 6.0E-02 95 3.93 1.01–15.3 3.3E202 0.03
miR-185 Het 1262 1.03 0.85–1.26 7.5E-01 2.4E-01 579 1.76 1.05–2.95 3.0E202 0.03
miR-195 HER2- 1105 0.64 0.53–0.78 1.1E205 4.1E-05 429 0.42 0.19–0.9 2.1E202 0.03
miR-204 Het 1262 0.66 0.54–0.80 2.9E205 7.3E-05 579 0.57 0.34–0.95 2.7E202 0.03
miR-205 Het 1262 0.78 0.64–0.95 1.3E202 7.6E-03 579 1.08 0.65–1.8 7.5E-01 0.33
miR-210 Het 1262 1.3 1.1–1.6 9.5E203 6.5E-03 579 1.85 1.11–3.09 1.7E202 0.03
miR-218 Het 1262 0.68 0.56–0.83 2.0E204 3.8E-04 579 0.53 0.32–0.88 1.2E202 0.03
miR-339-5p Het 1262 0.82 0.67–0.99 4.3E202 1.7E-02 – – – – –
miR-342-5p Het 1262 0.76 0.62–0.92 6.0E203 4.5E-03 – – – – –
miR-526b Het 1262 1.03 0.84–1.25 7.9E-01 2.5E-01 579 1.59 0.93–2.73 8.8E-02 0.07
miR-1258 Het – – – – – 579 0.55 0.32–0.9 2.0E202 0.03
MiRNA Patients GSE40267 GSE19783
n HR 95 % CI p value q value n HR 95 % CI p value q value
let-7b Het 85 0.81 0.48–1.37 4.3E-01 0.25 93 0.68 0.31–1.52 3.5E-01 0.83
let-7 g Het 85 1.11 0.66–1.88 6.9E-01 0.29 93 0.67 0.30–1.51 3.3E-01 0.83
miR-10b Het 85 1.45 0.86–2.46 1.6E-01 0.13 93 0.87 0.39–1.94 7.4E-01 0.88
miR-15a TNBC 53 0.94 0.49–1.79 8.4E-01 0.32 – – – – –
miR-21 TNBC 53 1.9 0.98–3.70 5.3E202 0.09 – – – – –
miR-22 Het 85 0.85 0.50–1.44 5.4E-01 0.27 93 0.79 0.36–1.77 5.7E-01 0.84
miR-27b TNBC 53 2.1 1.1–4.1 2.9E202 0.07 – – – –
miR-29c Het 85 0.57 0.33–0.96 3.1E202 0.07 93 0.47 0.21–1.07 6.6E-02 0.53
miR-99a LumA;ER?/HER2- – – – – – 47 0.19 0.041–0.918 2.1E202 0.40
Het 85 1.6 0.93–2.74 8.6E-02 0.10 93 0.82 0.37–1.82 6.2E-01 0.84
miR-100 Het 85 1.08 0.64–1.81 7.7E-01 0.31 93 0.78 0.35–1.73 5.3E-01 0.84
miR-101 Het 85 0.53 0.32–0.90 1.6E202 0.07 93 0.54 0.24–1.22 1.3E-01 0.53
miR-125b LumA; ER?/HER2- – – – – – 47 0.35 0.09–1.35 1.1E-01 0.53
miR-146a TNBC 53 0.66 0.35–1.27 2.1E-01 0.14 – – – – –
miR-146 TNBC 53 1.2 0.6–2.2 6.6E-01 0.29 – – – – –
miR-155 TNBC 53 0.65 0.34–1.24 1.9E-01 0.14 – – – – –
miR-181a TNBC 53 1.74 0.91–3.34 9.2E-02 0.10 – – – – –
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Kaplan–Meier plot is drawn. Importantly, the patients can be
filtered using major clinical parameters, such as receptor
status, molecular subtype, lymph node status, and histolog-
ical grade. Additionally, the analysis can be performed fil-
tering patients by the treatment received. Our tool allows the
selection of systemically untreated patients, representing a
real prognostic setting, and of patients treated with endocrine
therapy or chemotherapy. The web address of the online
service is available on the website: http://www.kmplot.com/
mirpower.
Validation of previously published survival-
associated miRNAs
MiRNAs reported to be associated with OS in breast cancer
tissues were identified using literature search. We com-
puted Kaplan–Meier plots for the selected 41 miRNAs to
validate their prognostic relevance in breast cancer (Online
Resource 4). Overall, we confirmed the previously found
association with OS for only 26 miRNAs (Table 1). Of
these, only two miRNAs (miR-29c and miR-101) were
prognostic in three datasets (Fig. 3; Table 1), while 5
miRNAs (miR-22, miR-195, miR-204, miR-210, miR-218)
and 19 miRNAs were associated with patient outcome in
two and one datasets, respectively (Table 1). It is worth
noting that the association with survival for miR-10b and
miR-22 were opposite to those reported in the literature.
Discussion
Oncogenic signaling pathways and gene expression profiles
have been associated with breast tumor development and
progression, and correlated with patient outcome [3, 15].
Even though novel technologies have accelerated the dis-
covery of potential biomarkers, starting to reshape research
directions, the identification of reliable prognostic
biomarkers still represents an issue of great clinical interest
in breast cancer research. Indeed, small sample size, clin-
ical and molecular heterogeneity of the data, inconsistent
performance of methodologies, and lack of technical
standardization have limited the identification of definitely
relevant prognostic markers in cancer patients. Thus, val-
idation should be essential prior to translate the identified
biomarkers into clinical practice. Recently, our group has
developed an integrative data analysis tool for the pre-
liminary assessment of prognostic biomarkers in breast,
ovarian, and non-small-cell lung cancers [16–18]. Beside
gene expression, miRNAs have emerged as a new class of
promising breast cancer biomarkers, as well as novel
molecular agents to be considered for different clinical
applications [5–10, 19–23].
In our study, we established a database integrating
miRNA expression data and clinical information derived
from four independent datasets of breast cancer. Finally,
we developed an online tool that allows a real-time analysis
to evaluate the prognostic value of these miRNAs in breast
cancer.
We demonstrated good performance capabilities of
miRpower through the validation of a complete list of
survival-associated miRNAs identified from a literature-
based research. In particular, we confirmed the reliable
association with OS for miR-29c and miR-101, which were
prognostic in three datasets, and for miR-22, miR-195, miR-
204, miR-210, miR-218, which were associated with patient
outcome in two datasets. Association with survival for
miR-10b and miR-22 was found to be opposite to those
reported in the literature [24, 25]. The differing results
Table 1 continued
MiRNA Patients GSE40267 GSE19783
n HR 95 % CI p value q value n HR 95 % CI p value q value
miR-185 Het 85 0.75 0.45–1.26 2.8E-01 0.18 93 1.25 0.56–2.82 5.9E-01 0.84
miR-195 HER2- 71 0.82 0.46–1.48 5.1E-01 0.27 68 0.48 0.18–1.3 1.4E-01 0.53
miR-204 Het 85 0.62 0.37–1.04 7.0E-02 0.10 93 1.03 0.46–2.30 9.4E-01 0.99
miR-205 Het 85 0.87 0.52–1.46 6.0E-01 0.28 93 1.4 0.6–3.1 4.6E-01 0.84
miR-210 Het 85 1.02 0.61–1.72 9.3E-01 0.34 93 1.16 0.52–2.59 7.2E-01 0.88
miR-218 Het 85 1.5 0.88–2.53 1.3E-01 0.12 93 0.97 0.43–2.16 9.4E-01 0.99
miR-339-5p Het 85 0.86 0.51–1.45 5.6E-01 0.27 93 1 0.45–2.22 9.9E-01 0.99
miR-342-5p Het 85 0.65 0.39–1.09 1.0E-01 0.10 93 0.62 0.27–1.39 2.4E-01 0.76
miR-526b Het 85 2.1 1.2–3.5 5.2E203 0.05 93 0.71 0.32–1.60 4.1E-01 0.84
miR-1258 Het – – – – – – – – – –
CI confidence interval, LumA luminal A, Het heterogeneous, ER? estrogen receptor-positive, HER2- human epidermal growth factor receptor
2-negative, HR hazard ratio, TNBC triple-negative breast cancer. p values B 0.05 are given in bold
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reported for miR-10b could be explained by differences in
the cohort of tumors used, statistical analysis adopted, and
an overall absence of consensus regarding the prognostic
ability of this miRNA. For instance, in a previous study, the
prognostic role of miR-10b was assessed using an expres-
sion value derived from a ratio between the miR-10b
expression levels in cancer tissues and paired normal tissue
[24]. Conversely, a different study demonstrated that miR-
10b expression did not correlate with the development of
distant metastases, relapse-free survival, and breast-cancer-
specific survival, suggesting that miR-10b is unlikely to
correlate with poor prognosis in breast cancer [26]. Our
findings suggest that miR-10b, although involved in tumor
invasion and metastasis, cannot be considered yet a reliable
predictor of OS in breast cancer, given its significant
association with outcome only in one dataset. Even though
several studies have suggested a tumor suppressive role for
miR-22 and an association with better outcome, other
studies demonstrated that miR-22 acts as an oncogene,
promoting epithelial-to-mesenchymal transition and an
aggressive metastatic disease, and correlates with poor
prognosis in breast cancer [25, 27, 28]. These data are in
line with our results, which can be considered reliable as
miR-22 was confirmed a prognostic marker in two distinct
Fig. 3 Validation of previously published prognostic miRNAs.
a Heatmap showing miRNAs with prognostic relevance in each
dataset. b Kaplan–Meier plots for miR-29c in breast cancer cohorts.
c Kaplan–Meier plots for miR-101 in breast cancer cohorts. Log-rank
p values and hazard ratios (HRs; 95 % confidence interval in
parentheses) are shown
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datasets. Thus, further analyses are needed to prove the
prognostic value of the expression of these two miRNAs in
breast cancer.
A second potential utility of miRpower is to generate de
novo hypothesis using one or more of the datasets as a
discovery set. There are certain caveats to keep in mind
during such an analysis—in particular those related to
unmeasured confounding variables and false discovery. A
solution for this second issue is provided using a separate
section of the online calculator enabling the computation of
false discovery rate—this section of the homepage imple-
ments statistical features described in our previous paper
[29].
Similar tools were recently developed to associate
miRNAs expression with clinical outcome [30–32]. How-
ever, miRpower has several advantages in the evaluation of
miRNAs as predictors of outcome in breast cancer patients.
Using a large cohort composed of 2178 breast cancer
patients, miRpower is the only tool acquiring data from
multiple independent datasets for a single tumor entity.
Having the highest number of patients increases statistical
power and the robustness of the results. In addition, the
selection of four studies meeting specific criteria provides
the capability to cross-validate the selected genes in inde-
pendent datasets. Furthermore, miRpower offers an
unprecedented flexibility, allowing the user to select a
priori group of patients to analyze. Indeed, before running
the analysis, patients can be filtered using clinical param-
eters, including ER, PGR, HER2 statuses, lymph node
involvement, and tumor grade. Importantly, our tool allows
the selection of systemically untreated patients, and
patients treated with endocrine therapy or chemotherapy,
clearing the identification of miRNAs that could impact
patient outcome in a specific clinical setting. We have to
note that almost all patients in the untreated cohort were
node negative and had a very good chance for a complete
response using surgery only. Finally, miRpower was
designed with a very intuitive interface, enabling also
researchers with no bioinformatic expertise to perform
survival analysis.
There are two limitations of miRpower we have to
mention. Firstly, only OS data were available for each
included dataset. In most settings, relapse-free survival is
essential as it has higher relevance for selection of the
optimal treatment. Secondly, only a fraction of about 20 %
of all miRNAs were measured in each of the four datasets
and more than half of all miRNAs were measured by only
one platform. Cross-validation in at least two independent
datasets is available for 498 miRNAs.
In conclusion, we have designed an easy-to-use bioin-
formatic tool capable of performing survival analyses for
the identification and validation of prognostic miRNAs in
breast cancer. We are planning to extend our platform by
integrating future datasets with upcoming clinical data and
providing additional statistical options. This resource rep-
resents a useful tool to support biomedical researchers in
the evaluation of prognostic power of miRNA-based
biomarkers.
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